INTRODUCTION {#S1}
============

Ion channels and transporters maintain ion gradients that enable the transport of metabolites across membranes and regulate diverse aspects of cellular physiology ([@R14]; [@R49]). Gain-of-function mutations or amplified expression of ion channels/transporters can drive cancer cell proliferation or disease progression ([@R4]; [@R12]; [@R46]; [@R60]; [@R67]). Cancer cells depend upon ion channels/transporters to regulate many cellular processes including intracellular calcium levels ([@R12]), pH ([@R75]), oxidative stress ([@R67]), mitochondrial function ([@R43]), proliferation ([@R49]), and cellular migration ([@R49]). Consequently, ion channels/transporters have been explored as potential therapeutic targets ([@R25]; [@R45]).

Endosomes and lysosomes are signaling hubs ([@R50]; [@R62]). Activated receptors accumulate and signal in endosomes, where adaptor proteins localize signaling molecules ([@R18]). Defects in endosome or lysosome function can alter the activation of signal transduction pathways, including the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways ([@R29]; [@R33]). Endosome and lysosome function are regulated by cation channels in their membranes, including TRPML1 ([@R7]; [@R8]; [@R72]). TRPML1, which is encoded by the gene *MCOLN1*, mediates the release of calcium (Ca^2+^), and potentially other cations, from lysosomes ([@R19]). It regulates multiple aspects of endolysosomal trafficking, phagocytosis, and the fusion of phagosomes with lysosomes ([@R16]; [@R57]). Loss of *MCOLN1* causes mucolipidosis type IV, a disease marked by defects in lysosomal storage and autophagy ([@R9]). The release of Ca^2+^ by TRPML1 also activates calcineurin, which promotes the activation of TFEB ([@R44]; [@R65]), a master regulator of lysosome biogenesis ([@R58]; [@R61]), and calmodulin, which promotes mammalian target of rapamycin complex 1 (mTORC1) activation ([@R36]). TRPML1 promotes MAPK pathway activation in head and neck cancer cells ([@R31]) and TORC1 activation in *Drosophila* cells ([@R77]) while reducing MAPK and PI3K pathway activation in astrocytes ([@R76]).

mTORC1 promotes cellular proliferation by activating anabolic pathways, such as protein synthesis, and by inactivating catabolic pathways, such as autophagy ([@R59]; [@R71]). mTORC1 is hyperactivated in some cells with lysosomal storage disorders ([@R3]). mTORC1 promotes the growth and proliferation of cancer cells, though it can inhibit the proliferation of amino acid-starved cells by suppressing macropinocytosis, the lysosome-mediated catabolism of proteins taken up from outside the cell ([@R48]). Macropinocytosis is promoted by MAPK pathway activation and can be an important source of amino acids in cancer cells ([@R1]; [@R15]; [@R32]; [@R48]). Indeed, cancer cells with MAPK pathway activation depend on autophagy for metabolic homeostasis ([@R27]; [@R53]).

Melanoma cells are particularly sensitive to the dysregulation of calcium homeostasis ([@R22]). Combined inhibition of the ATP1A1 sodium/potassium (Na^+^/K^+^) transporter and of the MAPK pathway dysregulates intracellular pH, mitochondrial Ca^2+^ levels, and mitochondrial function, leading to melanoma cell death ([@R22]). A clinical trial testing digoxin (an ATP1A1 inhibitor) and trametinib (a mitogen-activated protein kinase \[MEK\] inhibitor) in patients with advanced, refractory BRAF wild-type melanoma yielded a 20% response rate ([@R24]). To test whether there are other ion channels/transporters on which melanoma cells preferentially depend, we performed an *in vivo* screen. We found that TRPML1 is required by melanoma cells but not normal melanocytes. Surprisingly, TRPML1 promoted tumor formation by negatively regulating the MAPK pathway and mTORC1 signaling to sustain macropinocytosis and to promote protein homeostasis.

RESULTS {#S2}
=======

Melanoma Cells Preferentially Require *MCOLN1* {#S3}
----------------------------------------------

To identify ion channels/transporters on which melanoma cells preferentially depend, we performed an *in vivo* drop-out screen of a library of short hairpin RNAs (shRNAs) in xenografted melanomas. The library contained 2,589 shRNAs against 572 genes that encode ion channels/transporters, with 3 to 7 shRNAs per gene ([Table S1](#SD2){ref-type="supplementary-material"}). We infected melanomas from three patients (M214, M481, and M491) with 27 pools of shRNAs (\~100 shRNAs per pool), then transplanted the infected cells subcutaneously into NOD-SCID-*Il2rg*^−/−^ (NSG) mice, allowed tumors to form, and sequenced to compare the abundance of shRNAs in the tumors versus input cells ([Figure 1A](#F1){ref-type="fig"}). Each pool included two scrambled negative control shRNAs and three positive control shRNAs against a gene known to be required by melanoma cells (*EIF3A*) ([@R20]). The scrambled negative control shRNAs did not significantly change in abundance in tumors as compared to input cells ([Figures 1B](#F1){ref-type="fig"}--[1D](#F1){ref-type="fig"}) while the positive control shRNAs against *EIF3A* were significantly depleted ([Figures 1B](#F1){ref-type="fig"}--[1D](#F1){ref-type="fig"}). Based on our criteria ([Figure S1A](#SD1){ref-type="supplementary-material"}), we identified shRNAs against 40 genes that were significantly depleted in tumors as compared to input cells, suggesting these gene products were required by melanoma cells ([Figure S1B](#SD1){ref-type="supplementary-material"}).

We performed a secondary screen using 210 shRNAs against the 40 candidate genes, divided into 18 pools (\~12 shRNAs per pool). Again, the scrambled negative control shRNAs did not significantly change in abundance in tumors as compared to input cells ([Figures 1E](#F1){ref-type="fig"}--[1G](#F1){ref-type="fig"}), while the positive control shRNAs against *EIF3A* were significantly depleted ([Figures 1E](#F1){ref-type="fig"}--[1G](#F1){ref-type="fig"}). From this secondary screen, we identified shRNAs against 15 genes that were significantly depleted in the tumors as compared to input cells using the same criteria as in the primary screen ([Figures S1A](#SD1){ref-type="supplementary-material"} and [S1B](#SD1){ref-type="supplementary-material"}). We found a significant correlation between the results of the primary and secondary screens ([Figure S1C](#SD1){ref-type="supplementary-material"}).

All four shRNAs targeting *MCOLN1* were significantly depleted in tumors relative to input cells in the primary ([Figures 1B](#F1){ref-type="fig"}--[1D](#F1){ref-type="fig"}) and secondary ([Figures 1E](#F1){ref-type="fig"}--[1G](#F1){ref-type="fig"}) screens. In screens for essential genes, *MCOLN1* was not required for the survival of chronic myelogenous leukemia (CML) cells or Burkitt's lymphoma cells ([@R5]; [@R74]), raising the possibility it is preferentially required by melanoma cells. To test this, we infected melanoma cells from three patients with two shRNAs that efficiently knocked down *MCOLN1*/TRPML1 ([Figure 1K](#F1){ref-type="fig"}) or scrambled control shRNA, then injected the cells subcutaneously in NSG mice. Both shRNAs against *MCOLN1* significantly decreased the growth of tumors relative to control shRNA in all three melanomas ([Figures 1H](#F1){ref-type="fig"}--[1J](#F1){ref-type="fig"}). However, neither shRNA against *MCOLN1* significantly affected the growth of melanocytes from three donors ([Figure 1L](#F1){ref-type="fig"}). *MCOLN1* is thus required by melanoma cells but not normal melanocytes. Consistent with this, *MCOLN1* was more highly expressed by melanoma cells than melanocytes ([Figure 2A](#F2){ref-type="fig"}).

To independently assess whether *MCOLN1*/TRPML1 is required by melanoma cells, we deleted *MCOLN1* from melanoma cells using CRISPR. We generated three independent clones of *MCOLN1*-deficient melanoma cells from each of a melanoma cell line (A375) and two patient-derived melanomas (M214 and M481; [Figure S2A](#SD1){ref-type="supplementary-material"}). In each case, the *MCOLN1*-deficient clones had a 34-base pair deletion in exon 2, causing a frameshift mutation. Compared to parental cells, the *MCOLN1*-deficient clones had little *MCOLN1* mRNA ([Figures S2B](#SD1){ref-type="supplementary-material"}--[S2D](#SD1){ref-type="supplementary-material"}) and no detectable TRPML1 protein ([Figures 2B](#F2){ref-type="fig"}--[2D](#F2){ref-type="fig"}).

All of the *MCOLN1*-deficient melanoma cells grew significantly more slowly in culture as compared to parental cells ([Figures 2E](#F2){ref-type="fig"}--[2G](#F2){ref-type="fig"}), exhibiting significantly higher frequencies of activated caspase 3/7^+^ cells ([Figure 2H](#F2){ref-type="fig"}) and significantly lower frequencies of Ki-67^+^ proliferating cells ([Figure 2I](#F2){ref-type="fig"}). *MCOLN1* overexpression in the *MCOLN1*-deficient cells rescued the growth of these cells in culture ([Figures S2E](#SD1){ref-type="supplementary-material"}--[S2G](#SD1){ref-type="supplementary-material"}), demonstrating that their poor growth reflected a loss of *MCOLN1*/TRPML1 function rather than off-target mutations. After xenografting subcutaneously in NSG mice, all of the *MCOLN1*-deficient clones formed tumors that grew significantly more slowly as compared to parental cells ([Figures 2J](#F2){ref-type="fig"}--[2L](#F2){ref-type="fig"}). The *MCOLN1*-deficient tumors always contained significantly higher frequencies of activated caspase 3/7^+^ cells ([Figure 2M](#F2){ref-type="fig"}) and significantly lower frequencies of Ki-67^+^ proliferating cells ([Figure 2N](#F2){ref-type="fig"}) as compared to tumors formed by parental cells. *MCOLN1*/TRPML1 thus promoted the survival and proliferation of human melanoma cells *in vitro* and *in vivo*.

These observations may be relevant to patients as melanomas with above-average *MCOLN1* expression are associated with significantly worse survival as compared to melanomas with below-average *MCOLN1* expression ([Figure S3](#SD1){ref-type="supplementary-material"}).

Increased MAPK and mTORC1 Signaling {#S4}
-----------------------------------

Given that TRPML1 localizes to endosomal/lysosomal membranes ([@R72]), which serve as signaling hubs ([@R50]; [@R62]), we tested whether loss of *MCOLN1/*TRPML1 affected MAPK and PI3K pathway activation. *MCOLN1*-deficient melanomas consistently exhibited increased ERK (MAPK1), TSC2, and S6K (RPS6KB1) phosphorylation, and sometimes exhibited increased AKT phosphorylation, as compared to parental melanoma cells ([Figures 3A](#F3){ref-type="fig"}--[3C](#F3){ref-type="fig"}). Overexpression of *MCOLN1* in the *MCOLN1*-deficient melanomas rescued the increases in ERK and S6K phosphorylation ([Figures S2H](#SD1){ref-type="supplementary-material"}--[S2J](#SD1){ref-type="supplementary-material"}).

We treated *MCOLN1*-deficient and parental melanoma cells with the MEK inhibitor, trametinib. Trametinib blocked the increases in ERK, TSC2, and S6K phosphorylation in *MCOLN1*-deficient clones ([Figures 3D](#F3){ref-type="fig"}--[3F](#F3){ref-type="fig"}), suggesting that the increase in mTORC1 signaling was caused by the phosphorylation and inactivation of TSC2 by the MAPK pathway, as has been observed ([@R30]; [@R39]; [@R63]).

To assess why the MAPK pathway was more highly activated in *MCOLN1*-deficient as compared to parental melanoma cells, we examined the levels of phosphorylated MET and ERBB3. MET and ERBB3 are tyrosine kinase receptors that are highly expressed by melanoma cells, signal through the MAPK pathway, and promote melanoma cell proliferation ([@R11]; [@R69]; [@R70]). Activation of these receptors by ligand binding leads to their phosphorylation and internalization into endosomes, where they signal by activating ERKs, until the endosomes fuse with lysosomes and the receptors are degraded ([@R13]; [@R69]). Phosphorylated MET and ERBB3 levels were consistently elevated in *MCOLN1*-deficient as compared to parental melanoma cells ([Figures 3G](#F3){ref-type="fig"}--[3I](#F3){ref-type="fig"}). This suggested that *MCOLN1* deficiency may increase MAPK pathway activation at least partly by increasing receptor signaling, perhaps as a consequence of altered endosome trafficking or fusion with lysosomes.

To test whether there was altered endosome trafficking in *MCOLN1*-deficient melanoma cells, we assessed the colocalization of MET and ERBB3 with the endosomal and lysosomal markers, Rab7 and LAMP1 ([@R56]). *MCOLN1*-deficient cells showed significantly increased MET ([Figures 4A](#F4){ref-type="fig"}--[4D](#F4){ref-type="fig"}) and ERBB3 ([Figures S4A](#SD1){ref-type="supplementary-material"}--[S4D](#SD1){ref-type="supplementary-material"}) colocalization with Rab7 relative to parental cells, suggesting that MET and ERBB3 accumulate in endosomes. Although *MCOLN1*-deficient cells exhibited a perinuclear accumulation of MET and ERBB3, we observed no significant increase in MET or ERBB3 colocalization with LAMP1 relative to parental cells ([Figures 4E](#F4){ref-type="fig"}--[4H](#F4){ref-type="fig"} and [S4E](#SD1){ref-type="supplementary-material"}--[S4H](#SD1){ref-type="supplementary-material"}). These data suggest that *MCOLN1*-deficient cells exhibited increased MAPK pathway activation due to defects in endosome trafficking or lysosomal fusion.

To test whether pharmacological inhibition of endolysosomal fusion phenocopies the effects of *MCOLN1* deficiency, we treated cultured melanoma cells with bafilomycin A1, an inhibitor of endosomal and lysosomal fusion ([@R78]). Bafilomycin A1 treatment phenocopied *MCOLN1*/TRPML1 deficiency, increasing the levels of multiple receptor tyrosine kinases, activating MAPK and mTORC1 signaling, and inhibiting the expansion of the number of melanoma cells in culture ([Figures S5A](#SD1){ref-type="supplementary-material"}--[S5F](#SD1){ref-type="supplementary-material"}). These data suggest that TRPML1 promotes the survival and proliferation of melanoma cells by promoting normal endolysosomal function.

To test whether mTOR activation contributed to the poor proliferation and survival of *MCOLN1*-deficient melanoma cells, we treated *MCOLN1*-deficient and parental melanoma cells with the mTOR inhibitor, Torin1 ([@R68]). We used a relatively low concentration of Torin1 (5nM), that blocked the increase in S6K phosphorylation in *MCOLN1*-deficient cells without completely eliminating mTORC1 signaling ([Figures 5A](#F5){ref-type="fig"}--[5C](#F5){ref-type="fig"}). Torin1 treatment completely, or nearly completely, rescued the growth of *MCOLN1*-deficient cells in culture ([Figures 5D](#F5){ref-type="fig"}--[5F](#F5){ref-type="fig"}). Torin1 also rescued the growth of bafilomycin A1-treated melanoma cells in culture ([Figures S5D](#SD1){ref-type="supplementary-material"}--[S5F](#SD1){ref-type="supplementary-material"}).

To test if increased mTORC1 activation contributed to the poor growth of *MCOLN1*-deficient melanomas *in vivo*, we transplanted *MCOLN1*-deficient and parental melanoma clones subcutaneously in NSG mice. Once the tumors became palpable, we treated half of the mice daily with the mTORC1 inhibitor rapamycin. Rapamycin did not significantly affect the growth of tumors from parental lines but completely or nearly completely rescued the growth of *MCOLN1*-deficient tumors ([Figures 5G](#F5){ref-type="fig"}--[5I](#F5){ref-type="fig"}). Rapamycin treatment also rescued the increase in cell death observed in *MCOLN1*-deficient tumors ([Figures 5J](#F5){ref-type="fig"}--[5L](#F5){ref-type="fig"}). Therefore, *MCOLN1*/TRPML1 promoted tumor growth and the survival of melanoma cells by negatively regulating mTORC1 signaling.

TRPML1 Promotes Proteostasis {#S5}
----------------------------

mTORC1 activation promotes protein synthesis by increasing ribosome biogenesis and mRNA translation ([@R40]; [@R59]). We tested whether *MCOLN1*-deficient melanoma cells had increased protein synthesis as compared to parental cells by measuring the rate of O-propargyl-puromycin (OP-Puro) incorporation into cultured cells ([@R37]; [@R66]). *MCOLN1*-deficient melanoma cells exhibited significantly increased OP-Puro incorporation relative to parental cells, and this increase was blocked by treatment with Torin1 ([Figures 6A](#F6){ref-type="fig"}--[6C](#F6){ref-type="fig"}). This suggested that TRPML1 negatively regulates protein synthesis in melanoma cells by negatively regulating mTOR signaling.

To test whether the increased protein synthesis in *MCOLN1*-deficient melanoma cells contributed to their impaired growth, we treated *MCOLN1*-deficient and parental melanoma cells with a low dose of the protein synthesis inhibitor, puromycin. Treatment with puromycin blocked the increase in protein synthesis in *MCOLN1*-deficient cells ([Figures S6A](#SD1){ref-type="supplementary-material"}--[S6C](#SD1){ref-type="supplementary-material"}) and partially rescued the increase in cell death observed in these cells ([Figures S6G](#SD1){ref-type="supplementary-material"}--[S6I](#SD1){ref-type="supplementary-material"}) as well as their growth in culture ([Figures S6D](#SD1){ref-type="supplementary-material"}--[S6F](#SD1){ref-type="supplementary-material"}).

To better understand the mechanism by which increased protein synthesis led to cell death, we tested whether the *MCOLN1*-deficient melanoma cells experienced proteotoxic stress. We first assessed intracellular protein aggregation using Proteostat dye, which fluoresces upon binding to protein aggregates ([@R64]). *MCOLN1*-deficient melanoma cells exhibited increased Proteostat staining as compared to parental cells, and this difference was rescued by Torin1 treatment ([Figures 6D](#F6){ref-type="fig"}--[6I](#F6){ref-type="fig"}). *MCOLN1*-deficient cells also exhibited increased levels of BiP (HSPA5), increased phosphorylation of EIF2α (EIF2S1) and IRE1α (ERN1), and increased expression of ATF4 and CHOP (DDIT3), all consistent with the activation of an unfolded protein response ([@R73]). Treatment with Torin1 partially or completely rescued all of these changes ([Figures 6J](#F6){ref-type="fig"}--[6L](#F6){ref-type="fig"}). This suggested that *MCOLN1*-deficient melanoma cells experience proteotoxic stress as a consequence of increased mTORC1 signaling.

To test if clearing misfolded proteins could rescue the growth of *MCOLN1*-deficient cells, we treated with a proteasome activator, PD169316, a p38 MAPK (MAPK14) inhibitor that increases 26S proteasome (SEM1) activity ([@R35]). Treatment with PD169316 reduced the accumulation of protein aggregates in the *MCOLN1*-deficient cells ([Figures S6J](#SD1){ref-type="supplementary-material"}--[S6L](#SD1){ref-type="supplementary-material"}) and partially rescued their growth in culture ([Figures S6M](#SD1){ref-type="supplementary-material"}--[S6O](#SD1){ref-type="supplementary-material"}). Therefore, *MCOLN1*-deficiency impaired the growth of melanoma cells partly by increasing protein synthesis and inducing proteotoxic stress.

TRPML1 Promotes Macropinocytosis and Serine Homeostasis {#S6}
-------------------------------------------------------

Given that *MCOLN1*-deficiency impairs endolysosomal trafficking, phagocytosis, and the fusion of phagosomes with lysosomes ([@R16]; [@R57]) and that mTORC1 signaling can inhibit macropinocytosis ([@R32]; [@R48]), we tested if *MCOLN1* was necessary for macropinocytosis by melanoma cells. Using a self-quenching albumin that fluoresces upon degradation, DQ-BSA, we found melanoma cells engaged in significantly more macropinocytosis than melanocytes under the same culture conditions, even in medium not depleted for amino acids ([Figure S7](#SD1){ref-type="supplementary-material"}). *MCOLN1*-deficient cells exhibited significantly less macropinocytosis as compared to parental cells ([Figures 7A](#F7){ref-type="fig"}--[7D](#F7){ref-type="fig"}), and treatment with trametinib ([Figures 7A](#F7){ref-type="fig"} and [7C](#F7){ref-type="fig"}) or Torin1 ([Figures 7B](#F7){ref-type="fig"} and [7D](#F7){ref-type="fig"}) partially or completely rescued the reduction in macropinocytosis. *MCOLN1/*TRPML1 thus promoted macropinocytosis in melanoma cells partly by negatively regulating MAPK and mTOR signaling.

We wondered if the increased protein synthesis and decreased macropinocytosis in *MCOLN1*-deficient melanoma cells would affect amino acid homeostasis. To test this, we performed metabolomics in parental and *MCOLN1*-deficient melanoma cells, with and without Torin1 treatment in culture. The only metabolite that was significantly depleted in cultured *MCOLN1*-deficient melanoma cells from all three lines and rescued by Torin1 treatment was serine ([Figure 7E](#F7){ref-type="fig"}). Serine is required for protein, nucleotide, lipid, and glutathione synthesis ([@R38]), and cells can use antiporters to exchange serine for other amino acids ([@R17]). Metabolomic analysis of subcutaneous tumors grown from parental and *MCOLN1*-deficient melanoma cells confirmed that serine was depleted in *MCOLN1*-deficient tumors *in vivo* and that rapamycin treatment rescued this serine depletion ([Figure 7F](#F7){ref-type="fig"}; [Table S2](#SD3){ref-type="supplementary-material"}). Supplementation of the culture medium with increased L-serine (2 versus 0.4 mM in normal medium) did not significantly affect the growth of parental cells but rescued the growth of *MCOLN1*-deficient cells ([Figures 7G](#F7){ref-type="fig"}--[7I](#F7){ref-type="fig"}). *MCOLN1/* TRPML1 thus promoted the maintenance of intracellular serine levels by negatively regulating mTORC1 signaling, reducing protein synthesis, and increasing macropinocytosis ([Figure 7J](#F7){ref-type="fig"}).

DISCUSSION {#S7}
==========

Our data suggest that melanoma cells increase TRPML1 expression relative to normal melanocytes ([Figure 2A](#F2){ref-type="fig"}) and that TRPML1 promotes tumor formation by negatively regulating MAPK and mTORC1 signaling ([Figures 3A](#F3){ref-type="fig"}--[3C](#F3){ref-type="fig"}). Our findings suggest that TRPML1 does this by regulating endolysosomal trafficking and fusion, but there could also be additional mechanisms by which TRPML1 inhibits ERK signaling. While cancer cells depend upon the activation of oncogenic signaling pathways, activation of these pathways can have deleterious consequences that impair proliferation and survival ([@R2]; [@R6]; [@R10]; [@R23]; [@R51]). Melanoma cells almost always exhibit MAPK pathway activation ([@R47]) but appear to upregulate TRPML1 to avoid overactivation. The increased MAPK pathway and mTORC1 activation in TRPML1-deficient melanoma cells reduced macropinocytosis, increased protein synthesis, depleted serine, and induced proteostatic stress.

TRPML1 is also required for the proliferation of head and neck cancer cells with HRAS mutations ([@R31]). However, in contrast to our results, *MCOLN1*/TRPML1 deficiency reduced MAPK pathway activation in those cells by attenuating HRAS clustering. In melanoma, TRPML1 deficiency increased MAPK pathway activation. Increased MAPK and PI3K pathway activation was also observed in astrocytes from *Mcoln1*-deficient mice, though it is unclear whether this reflected a cell-autonomous effect of TRPML1 deficiency or increased levels of inflammatory cytokines ([@R76]). The opposite results in different cell types may reflect distinct effects of TRPML1 on HRAS signaling, which is not mutated in melanoma ([@R28]), or other differences between cells.

It is striking that melanoma cells increased both macropinocytosis ([Figure S7](#SD1){ref-type="supplementary-material"}) and TRPML1 expression ([Figure 2A](#F2){ref-type="fig"}) relative to normal melanocytes, even in the absence of amino acid starvation. *MCOLN1/TRPML1*-deficient melanoma cells exhibited serine depletion that contributed to their poor growth in culture ([Figures 7E](#F7){ref-type="fig"}--[7I](#F7){ref-type="fig"}). The increased protein synthesis ([Figures 6A](#F6){ref-type="fig"}--[6C](#F6){ref-type="fig"}) and decreased macropinocytosis ([Figures 7A](#F7){ref-type="fig"}--[7D](#F7){ref-type="fig"}) in *MCOLN1*-deficient cells may have caused the serine depletion. Serine may also be more sensitive to depletion because amino acid-starved cells sometimes exchange serine for other amino acids ([@R17]). Nonetheless, it is also possible that *MCOLN1* deficiency impaired serine biosynthesis. The dependence of melanoma cells upon TRPML1 to attenuate MAPK/mTORC1 signaling, to sustain macropinocytosis, and to prevent proteotoxic stress reveals a new vulnerability.

STAR★METHODS {#S8}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S9}
---------------------------------------

The TRPML1-GFP plasmid generated in this study has been deposited to Addgene. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Sean Morrison (<sean.morrison@utsouthwestern.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S10}
--------------------------------------

### Melanoma specimen collection and enzymatic dissociation {#S11}

Melanoma specimens were obtained with informed consent from all patients according to protocols approved by the Institutional Review Board of the University of Michigan Medical

School (IRBMED approvals HUM00050754 and HUM00050085) and the University of Texas Southwestern Medical Center (IRB approval 102010--051). The M214 and M481 melanoma specimens were obtained from male patients and M491 was obtained from a female patient. Single cell suspensions were obtained by mechanically dissociating tumors, enzymatically digesting in 200 U/ml collagenase IV (Worthington), DNase (50 U/ml) and 5 mM CaCl~2~ for 20 min at 37°C, and filtering through a 40-μm cell strainer.

### Mouse studies and xenograft assays {#S12}

All mouse experiments were performed according to protocols approved by the

Institutional Animal Care and Use Committee at UT Southwestern Medical Center (protocol 2016--101360). Melanoma cell suspensions were prepared for injection in 50μl of L15 medium containing 1 mg/ml bovine serum albumin, 1% penicillin/streptomycin, and 10 mM HEPES (pH 7.4), and 25% high-protein Matrigel (Fisher Scientific). Subcutaneous injections were performed in the flanks of NOD.CB17-Prkdc^scid^ Il2rg^tm1Wjl^/SzJ (NSG) mice. Four to eight-week-old NSG mice were transplanted with 100 melanoma cells subcutaneously unless otherwise specified. Mouse cages were randomized between treatments (mice within the same cage received the same treatment). Both male and female mice were used. Subcutaneous tumor diameters were measured weekly with calipers until any tumor in the mouse cohort reached 2.5 cm in its largest diameter. At that point, all mice in the cohort were killed for analysis.

For *in vivo* treatment with mTOR inhibitor, the mice were administered rapamycin (LC Laboratories) by oral gavage beginning when the subcutaneous tumors became palpable (5 mg/kg/day in 200 μL of 0.5% hydroxypropyl methyl cellulose with 0.2% Tween80 and 1% DMSO). Tumor growth was monitored weekly with a caliper. Mice were killed for analysis by the time the primary tumor reached 2.5 cm in its largest diameter, or when the mice exhibited signs of distress, whenever was earlier.

### Primary melanoma cell cultures {#S13}

A375 (ATCC; CRL-1619; female), M214 (female), M481 (male), and M491 (male) melanoma cells and melanocytes from three donors (hMEL1 (ATCC; PCS-200--013), hMEL2 (Invitrogen; C-024--5C), hMEL3 (Lonza; CC-2586)) were cultured in tissue-culture-treated plates (Corning) with high-glucose DMEM (GIBCO), 10% fetal bovine serum (FBS; Gemini) and 1% penicillin/streptomycin (Fisher). The sex of the melanocyte donors was not available. All cultures were incubated at 37°C in 5% CO~2~ and constant humidity. Cells were passaged for 1 to 3 months and used for experiments. All cell lines tested negative for *Mycoplasma* using the MycoAlert detection kit (Lonza), and the identities of all cell lines were verified using short tandem repeat (STR) profiling in March 2019. To assess the effects of Torin1 (Tocris), Puromycin (Sigma), PD169316 (Sigma), or L-serine (Sigma) on the growth of cells, 1000 parental or *MCOLN1*-deficient cells were added to each well of a 24-well plate. The small molecules were added 24 hours later, then the cells were counted using a hemocytometer (Hausser Scientific) after 7, 14, or 21 days. The medium was changed every 3--4 days. To assess the effect of bafilomycin A1 (Sigma) and/or Torin1 on melanoma cells ([Figure S5](#SD1){ref-type="supplementary-material"}), 100,000 melanoma cells were added to each well of a 6-well plate and the drugs were added 24 hours later. After another 48 hours, the cells were counted and protein lysates were collected.

### CRISPR editing of MCOLN1 in melanoma cells {#S14}

Single guide RNAs (sgRNAs) targeting exon 2 of human *MCOLN1* were designed using publicly available tools (<https://zlab.bio/guide-design-resources>): *MCOLN1* sgRNA \#1 5′ -- TCGCCGTCGTCTCAAATACT -- 3′*MCOLN1* sgRNA \#2 5′ -- TGCGACAAGTTTCGAGCCAA-- 3′

The sgRNAs were cloned into the U6-driven Cas9 expression vector (pX458-pSpCas9(BB)-2A-GFP; 48318, Addgene) ([@R55]). sgRNA insertion was confirmed by Sanger sequencing.

Approximately 100,000 -- 500,000 melanoma cells were plated in tissue-culture-treated 6-well plates in DMEM plus 10% FBS and 1% penicillin/streptomycin. 1 μg of each of the two sgRNA constructs was co-transfected into the melanoma cells using polyjet (SignaGen) according to the manufacturer's instructions. After 36--48 hours, GFP^+^ cells were flow cytometrically isolated and allowed to recover for 24--48 hours in DMEM plus 10% FBS and 1% penicillin/streptomycin. Single cells were then plated in tissue-culture-treated 96-well plates in Prime-XV tumorsphere medium (Irvine Scientific) supplemented with 2 U/ml Heparin (Sigma), 0.1 μg/ml Hydrocortisone (Sigma), 2% B27 (Thermo Fisher), 1 μM StemRegenin 1 (StemCell Technologies, Inc.), 10% charcoal stripped FBS (Thermo Fisher), 10 μg/ml Bovine Pituitary Extract (BPE; Lonza), 10 ng/ml recombinant human IL-8 (CXCL8; Peprotech), 20 ng/ml recombinant human GRO-α/MGSA (CXCL1; Peprotech), and 25 ng/ml recombinant human HGF (Peprotech). Genomic DNA was isolated from individual clones with QuickExtract (Epicenter), and clones were screened and sequenced for *MCOLN1* deletions.

METHOD DETAILS {#S15}
--------------

### qPCR {#S16}

For quantitative reverse transcription PCR (qPCR), RNA from 100,000 melanoma cells was extracted (QIAGEN) and reverse transcribed into cDNA using SuperScript III (Invitrogen). qPCR was performed using a Roche LightCycler480. The primers used for qPCR analysis for *MCOLN1* were: 5′- CTGATGCTGCAAGTGGTCAAG-3′ (Forward) and 5′- GGTGTTCTCTTCCCGGAATGTC-3′ (Reverse).

### Antibody staining and flow cytometry {#S17}

All melanomas expressed DsRed and luciferase ([@R52]). All antibody labeling was performed for 20 min on ice, followed by washing with HBSS and centrifugation at 200×g for 5 min. Cells were stained with directly-conjugated antibodies against mouse CD45 (75--0451-U100; 30-F11-violetFluor450; Tonbo), mouse CD31 (48-0311-82; 390-eFluor450; eBiosciences), mouse Ter119 (75--5921-U100; TER-119-violetFluor450; Tonbo) and human HLA-A, B, C (555555; G46--2.6-APC; BD Biosciences). Human melanoma cells were identified and isolated as cells that were positive for DsRed and HLA and negative for mouse CD45, CD31, and Ter119. Cells were resuspended in 4',6-diamidino-2-phenylindole (DAPI; 1 μg/ml; Sigma) to eliminate dead cells from sorts and analyses. Cells were analyzed or sorted on a FACS Fusion cell sorter (Becton Dickinson), a FACS Aria II SORP cell sorter (Becton Dickinson), or a FACS Canto RUO cell analyzer (Becton Dickinson).

For flow cytometric analysis of activated Cas3/7 staining, cultured melanoma cells were trypsinized with a 0.25% trypsin solution (Fisher) or tumors were enzymatically dissociated as described above. Equal numbers of melanoma cells (500,000--2,000,000) were loaded with 1 μM CellEvent Caspase-3/7 Green in HBSS (Ca^2+^- and Mg^2+^-free). Cells were stained for 15--30 min at 37°C. Staining was assessed by flow cytometry, gating on live melanoma cells (positive for human HLA and DsRed and negative for DAPI and mouse CD45/CD31/Ter119).

### Ki-67 staining to evaluate proliferation {#S18}

To assess Ki-67 staining in cultured cells, melanoma cells were grown in 8-well Lab-Tek II Chamber Slides (Thermo). Cells were washed with cold PBS and fixed in 4% paraformaldehyde (Fisher) for 15 min at room temperature. For *in vivo* experiments, tumor specimens were fixed in 4% paraformaldehyde overnight at 4°C, cryoprotected in 30% sucrose (Sigma) overnight, and frozen in OCT (Fisher). Sections (10 μm) were cut using a cryostat. Cells or tissue sections were permeabilized with PBS supplemented with 0.05% Triton X-100 for 5 min, washed with PBS, and blocked in 5% goat serum (JacksonImmuno) in PBS for 1 hour at room temperature. Cells or tissue sections were then stained with anti-Ki67 antibody (M7240, Dako, 1:100) overnight at 4°C, washed in PBS, stained with secondary antibody (Alexa Fluor 488-AffiniPure F(ab')2 Fragment goat anti-mouse IgG; Life Technologies; 1:1000) for 1 hour in the dark at room temperature, washed again in PBS, stained with 1 μg/ml DAPI, and mounted with Fluoromount-G (SouthernBiotech) for confocal imaging.

### Lentiviral shRNA library transduction {#S19}

Lentiviral shRNA constructs against ion channels and transporters from throughout the human genome were assembled from multiple sources. The GIPZ Human Ion Channel shRNA library (1,881 shRNAs; Dharmacon, RHS6045) was supplemented with two custom libraries comprised of shRNAs targeting channels and transporters that were not included in the Ion Channel shRNA library (301 shRNAs from Dharmacon and 393 shRNAs from the pGIPZ shRNAmir library from Dharmacon).

For *MCOLN1* knockdown, Dharmacon shRNA clones V3LHS_338980 and V2LHS_249668 were used. For *MCOLN1* overexpression, the human *MCOLN1* open reading frame (HsCD00732386, DNAsu) was cloned into a lentiviral expression construct (pLOC-tRFP-IRES-tGFP; Dharmacon) using the In-Fusion HD cloning system (Clontech). The *MCOLN1* gain and loss-of-function constructs were verified by Sanger sequencing.

For virus production, 0.9 mg of the appropriate plasmid along with 1 μg of helper plasmids (0.4 μg pMD2.G and 0.6 mg of psPAX2) were transfected into 293T cells using polyjet. The viral supernatants were collected 48 hours after transfection and filtered through a 0.45 mm filter. Freshly dissociated melanoma cells (300,000 to 1,000,000) were infected with viral supernatants supplemented with 10 μg/ml polybrene (Sigma) for 4 to 6 hours and cultured in DMEM plus 10% FBS and 1% penicillin/streptomycin for 48 hours to allow GFP expression. DsRed^+^/GFP^+^ cells were sorted and transplanted into NSG mice to assess tumor growth.

### *In vivo* shRNA screens {#S20}

shRNA drop-out screens were conducted as previously described ([@R26]). For the primary screen, a library of 2,589 shRNAs was divided into 27 pools of \~100 shRNAs/pool. Two negative control scrambled shRNAs (Dharmacon, RHS4349 and RHS4346) and three positive control shRNAs targeting *EIF3A* (Dharmacon, V2LHS_23910, V2LHS_23911, and V2LHS_23913) were spiked into each pool to serve as internal controls. For each pool, shRNA lentivirus was produced in 293T cells as described above, and 5--10 million freshly dissociated melanoma cells from each of three patients (M214, M481, and M491) were transduced. After 48 hours in culture, GFP^+^ cells were sorted. We have previously demonstrated that at least 1 in 4 human melanoma cells form tumors after subcutaneous transplantation into NSG mice ([@R54]). Based on this, 100,000 GFP^+^ melanoma cells were subcutaneously injected into each of 4 NSG mice per shRNA pool per melanoma so that an average of 1,000 melanoma cells would express each shRNA in each pool injected into a single mouse in the primary screen, and that at least 250 melanoma cells expressing each shRNA would have an opportunity to contribute to each tumor. Once the tumors reached 1.0 -- 1.5 cm in diameter, they were surgically excised, and genomic DNA was isolated (Zymo) from equal numbers of input cells and tumor cells. Two aliquots of 100,000 cells per pool per melanoma were analyzed to quantify shRNA abundance among input cells. shRNA barcodes were PCR amplified. The resulting PCR products were purified by gel extraction (QIAGEN) and sequenced using a NextSeq 500 (Illumina) to compare the abundance of each shRNA in the input cells as compared to the tumors.

Sequencing results were analyzed as previously described ([@R26]). Raw sequences were trimmed using cutadapt ([@R42]) and mapped using Bowtie 2 ([@R34]). Raw reads for each shRNA were normalized to the total number of reads in the corresponding sample. t tests were performed on the log~2~-transformed counts with multiple comparisons adjustments to compare the normalized abundance of each shRNA in the input cells as compared to tumors.

For the secondary screen, 210 shRNAs targeting the 40 candidate genes identified in the primary screen were assembled into a new library, which was then divided into 18 pools of \~17 shRNAs each (including 2 negative and 3 positive control shRNAs, as described above, in each pool). Virus production, transduction, and sorting of melanoma cells were performed as described above. 10,000 GFP^+^ cells were subcutaneously injected into each of 3 NSG mice per pool per melanoma so that an average of nearly 600 melanoma cells would express each shRNA upon injection into each mouse, and that approximately 150 melanoma cells expressing each shRNA would have an opportunity to contribute to the formation of each tumor. Three aliquots of 100,000 cells per pool per melanoma were analyzed as input cells. Genomic DNA isolation, barcode amplification, and sequencing were performed as described above.

### Western blot analysis {#S21}

For culture experiments, melanoma cells were grown adherently, washed with PBS, and directly lysed in the culture dishes using RIPA Buffer (Cell Signaling Technology) or Triton lysis buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with phenylmethylsulphonyl fluoride (Sigma) and protease and phosphatase inhibitor cocktail (Roche). For *in vivo* experiments, tumors were surgically excised and snap frozen in liquid nitrogen. Tumor samples were lysed in lysis buffer in 1.7 mL Eppendorf tubes with disposable pestles (Kontes). The bicinchoninic acid (BCA) protein assay (Thermo) was used to quantify protein concentrations. Equal amounts of protein (5--20 μg) were loaded into each lane and separated on 4%--20% polyacrylamide tris glycine SDS gels (BioRad), then transferred to polyvinylidene difluoride (PVDF; BioRad) membranes. Membranes were blocked for 1 hour at room temperature with 5% bovine serum albumin (BSA) in TBS supplemented with 0.1% Tween20 (TBST) and then incubated with primary antibodies overnight at 4°C. Membranes were then washed and incubated with horseradish peroxidase conjugated secondary antibody (Cell Signaling Technology) for 1h at room temperature, then washed again. Signals were developed using Clarity Western ECL Substrate (BioRad) or SuperSignal West (Thermo Fisher). Blots were sometimes stripped using Restore stripping buffer (Thermo Fisher) and re-stained with other primary antibodies.

### Colocalization studies {#S22}

For analysis of colocalization between receptor tyrosine kinases (MET and ERBB3) and late endosomal or lysosomal markers (Rab7 and LAMP1, respectively), 10,000 to 30,000 melanoma cells were plated in 8-well Lab-Tek II Chamber Slides (Thermo). Cells were washed with cold PBS and fixed in 4% paraformaldehyde (Fisher) for 15 min at room temperature, permeabilized with PBS supplemented with 0.05% Triton X-100 for 5 min, washed with PBS, and blocked in 5% donkey serum (JacksonImmuno) in PBS for 1 hour at room temperature. Cells or tissue sections were then co-stained with either rabbit anti-MET (8198, Cell Signaling, 1:200) or rabbit anti-ERBB3 (12708, Cell Signaling, 1:200) combined with mouse anti-Rab7 (95746, Cell Signaling, 1:100) or mouse anti-LAMP1 (sc-20011, Santa Cruz, 1:100) primary antibodies overnight at 4°C. The next day, cells were washed in PBS, stained with secondary antibodies (Alexa Fluor 488 donkey anti-rabbit IgG and Alexa Fluor 647 donkey anti-mouse IgG; Life Technologies; 1:1000) for 1 hour at room temperature, washed again in PBS, stained with 1 μg/ml DAPI, and mounted with Fluoromount-G (SouthernBiotech) for confocal imaging.

Randomly selected melanoma cells were imaged using Z stacks with a 40× objective and 2048 × 2048 pixel resolution on a Zeiss LSM780 Inverted confocal microscope. Deconvolution of the Z stack images was performed using the Bitplane Imaris v7.7.2 and AutoQuant X3 softwares. Background was subtracted from each image using Imaris v7.7.2. Colocalization was assessed in individual cells using the Imaris surface function and a 3D colocalization analysis was performed using the Imaris Coloc tool. Manders colocalization coefficients were used to quantify the degree of colocalization of two fluorophores per cell ([@R21]; [@R41]).

### Measurement of the rate of protein synthesis {#S23}

For analysis of the rate of protein synthesis in culture, 100,000 -- 500,000 melanoma cells were plated in 12-well tissue-culture-treated plates containing DMEM plus 10% FBS and 1% penicillin/streptomycin. When specified, cells were cultured for 24 hours in 5 nM Torin1 or 0.5 ng/ml puromycin prior to addition of OP-Puromycin to assess the rate of protein synthesis. 50 μM OP-Puromycin (Medchem Source) was added to the culture medium for 30 minutes. Cells were washed twice in cold PBS, trypsinized, and centrifuged at 300×g for 5 minutes to pellet. The cells were resuspended in 250 μl of 1% paraformaldehyde (Affymetrix) in PBS for 15 min on ice. Cell were then washed in PBS, and permeabilized in 100 μl of PBS supplemented with 3% FBS and 0.1% saponin (Sigma) for 5 min at room temperature. The azide-alkyne cycloaddition to quantify OP-Puro incorporation into nascent peptides was performed using the Click-iT Cell Reaction Buffer Kit (Thermo Fisher) with azide conjugated to Alexa Fluor 555 (Life Technologies) at 5 mM final concentration. After the 30 min azide-alkyne cycloaddition reaction, the cells were washed twice in PBS supplemented with 3% FBS and 0.1% saponin, then resuspended in PBS with 1 μg/ml DAPI and analyzed by flow cytometry.

### Measurement of protein aggregation {#S24}

Protein aggregation was measured with the Proteostat Aggresome Detection Kit (Enzo). Melanoma cells were plated in 8-well Lab-Tek II Chamber Slides (Thermo) in DMEM plus 10% FBS and 1% penicillin/streptomycin. When specified, cells were cultured for 24 hours in 5 nM Torin1 or 5 μM PD169316 proteosome activator before being fixed. Cells were washed with PBS, fixed in 4% formaldehyde (Fisher) for 30 min at room temperature, washed twice with PBS, permeabilized in 1X Assay Buffer (Enzo) supplemented with 0.5% Triton X-100 and 3mM EDTA, pH 8.0, for 30 min at 4°C, and washed twice with PBS. Cells were then stained with the Proteostat Dual Detection Reagent (Enzo) for 30 min in the dark at room temperature. Cells were carefully washed twice in PBS, stained with 1 μg/ml DAPI, and mounted with Flouromount-G for confocal imaging. Protein aggregation was quantified by calculating the integrated signal density per cell in randomly chosen fields of view throughout each sample using ImageJ.

### Measurement of macropinocytosis in culture by imaging of live cells {#S25}

As previously described ([@R48]), melanoma cells or human melanocytes were plated in 8-well chamber slides (Ibidi) containing DMEM plus 10% FBS and 1% penicillin/streptomycin. When specified, cells were pre-treated with 5 nM Torin1 or trametinib (Selleckchem) for 24 hours before addition of DQ-BSA (0.3 mg/ml DQ Green BSA; Thermo) to the culture medium to quantify macropinocytosis. Cells were imaged after 5--6 hours of incubation with DQ-BSA using a Zeiss LSM780 Inverted confocal microscope. One hour before imaging, 0.2 μg/ml Hoechst 33342 (Thermo) was added to visualize nuclei. Cellular degradation of fluorescently labeled albumin was determined by calculating the integrated signal density per cell in randomly chosen fields of view throughout each sample using ImageJ.

### LC-MS/MS metabolomic analysis {#S26}

Cultured melanoma cells or subcutaneous tumor fragments were homogenized using pestles in 1.7 mL Eppendorf tubes in ice-cold 80:20 methanol:water (vol:vol) and vortexed vigorously. The supernatant was collected into fresh Eppendorf tubes after a 15 min centrifugation at 17,000×g at 4°C and placed directly into autosampler vials for analysis by LC/MS without drying in a speed-vac. Metabolite measurements were carried out on a Thermo Scientific (Bremen, Germany) QExactive HF-X hybrid quadrupole orbitrap high resolution mass spectrometer (HRMS) coupled to a Vanquish UHPLC. Chromatographic separation of metabolites was achieved using a Millipore (Burlington, MA) ZIC-pHILIC column (5 μm, 2.1 × 150 mm) with a binary solvent system of 10 mM ammonium acetate in water, pH 9.8 (Solvent A) and acetonitrile (Solvent B) with a constant flow rate of 0.25 ml/minute. For gradient separation, the column was equilibrated with 90% Solvent B. After injection, the gradient proceeded as follows: 0--15 minutes linear ramp from 90% B to 30% B; 15--18 minutes isocratic flow of 30% B; 18--19 minutes linear ramp from 30% B to 90% B; 19--27 minutes of column regeneration with isocratic flow of 90% B. HRMS data were acquired with two different methods. Individual samples were acquired with an HRMS full scan (precursor ion only) switching between positive and negative polarities. Polarity-switching HRMS full scan data were acquired with a resolving power of 60,000 FWHM and a mass range of 50--750 Daltons; the AGC target was set to 10^6^ and a maximum injection time of 100 ms. Pooled samples, which were used for structural verification of the identity of metabolite peaks, were generated from an equal mixture of all individual samples and were analyzed using individual positive- and negative polarity data-dependent high-resolution tandem mass spectrometry (ddHRMS/MS) for high confidence metabolite identification. For ddHRMS/MS methods, precursor ion scans were acquired at a resolving power of 60,000 FWHM, with a mass range of 50--750 Daltons. The Automated Gate Control (AGC) target value was set to 10^6^, with a maximum injection time of 100 ms. Product ion spectra were acquired at a resolving power of 15,000 FWHM without a fixed mass range. The AGC target value was set to 2 × 10^5^ with a maximum injection time of 150 ms. Data dependent parameters were set to acquire the top 10 ions with a dynamic exclusion of 15 s and a mass tolerance of 5 ppm. Isotope exclusion was turned on and the normalized collision energy was set to a constant value of 30. Settings remained the same in both polarities.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S27}
---------------------------------------

### Statistical Methods {#S28}

Generally, multiple melanomas derived from different patients or cell lines were tested in multiple independent experiments performed on different days. Mice were allocated to experiments randomly and samples processed in an arbitrary order, but formal randomization techniques were not used. Prior to analyzing the statistical significance of differences among treatments, we tested whether data were normally distributed and whether variances were similar among treatments. To test for normality, we performed the Shapiro--Wilk tests when 3 ≤ n \< 20 samples or the D'Agostino tests when n ≥ 20 samples. To test whether variability significantly differed among treatments, we performed *F*-tests (for experiments with two treatments) or Levene's median tests (for experiments with more than two treatments). When the data were not significantly deviated from normality (p ≥ 0.01) and variability not significantly differed among treatments (p ≥ 0.05), we performed parametric tests such as Student's t tests (for experiments with two treatments) or one-way ANOVAs (for experiments with more than two treatments) on the original data. When the data were not significantly deviated from normality, but variability significantly differed among treatments, we performed parametric tests with the Welch's method for variance adjustment. When the data were significantly deviated from normality, we log~2~-transformed the data and tested again for normality and variability. If the transformed data no longer significantly deviated from normality, we then performed parametric tests with or without the Welch's method for variance adjustment on the transformed data. If the log~2~-transformation was not possible or the transformed data still significantly deviated from normality, we performed non-parametric tests on the non-transformed data. Ratio data were always log~2~-transformed before any statistical tests were performed. Statistical tests were always two-tailed when this option was applicable. For experiments with two factors and data significantly deviated from normality, we reduced the factors to one when no appropriate non-parametric, two-way statistical tests were available.

To assess the enrichment of shRNAs in the input cells as compared to tumors in the shRNA screen, we performed multiple unpaired, two-tailed t tests on the log~2~-transformed, total-count normalized data ([@R26]). To assess differences in tumor growth or cell growth in culture, we performed one-way or two-way ANOVAs on the last time point measured. To assess the difference between survival curves, we performed the Mantel-Cox's log-rank test. To assess the reproducibility of shRNA screen experiments, we performed the Spearman's correlation test. To assess the difference between two groups comprised of multiple different melanoma or melanocyte lines, we performed the two-tailed, nested t test. When applicable, multiple-comparisons adjustments were always performed after statistical tests.

All statistical analyses were performed with Graphpad Prism 8 or R 3.5.1 with the stats, fBasics and car packages. All data represent mean ± standard deviation. No data were excluded. Mice sometimes died during experiments, presumably due to the growth of metastatic tumors. In those instances, data that had already been collected from those mice in interim analyses were included (such as subcutaneous tumor growth measurements over time).

DATA AND CODE AVAILABILITY {#S29}
--------------------------

Original data for the shRNA screens are available on Mendeley Data (<https://doi.org/10.17632/ndxtvbg4ty.1>).
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![An *In Vivo* shRNA Screen Identified *MCOLN1* as Being Preferentially Required by Melanoma Cells\
(A) Melanoma cells from three patients (M214, M481, and M491) were transduced with 27 pools of shRNAs targeting ion channels and transporters throughout the human genome. 100,000 infected cells were subcutaneously transplanted into each of 4 NSG mice per pool (324 NSG mice total).\
(B--D) In the primary screen of 2,589 shRNAs, shRNAs targeting *MCOLN1* (red) were significantly depleted in tumors relative to input cells and in tumors relative to scrambled negative control shRNAs (black) in M214 (B), M481 (C), and M491 (D). Positive control shRNAs against *EIF3A* (blue) were also significantly depleted.\
(E--G) In the secondary screen of 210 shRNAs, shRNAs targeting *MCOLN1* (red) were significantly depleted in tumors relative to input cells and in tumors relative to scrambled negative control shRNAs (black) in M214 (E), M481 (F), and M491 (G). Positive control shRNAs against *EIF3A* (blue) were also significantly depleted.\
(H--J) Growth of subcutaneous tumors in mice transplanted with M214 (H), M481 (I), and M491 (J) expressing scrambled control shRNA (black) or two shRNAs against *MCOLN1* (red and blue). The data represent mean ± SD from one representative experiment (of two performed) with 5 mice per shRNA per melanoma.\
(K) Western blot analysis of TRPML1 and β-actin in melanoma cells expressing two shRNAs against *MCOLN1* versus scrambled negative control shRNA. The numbers (1--4) represent tumors from four replicate mice per treatment. The blot reflects one representative experiment (of two performed).\
(L) Growth in culture of primary human melanocytes from three donors (hMEL1, hMEL2, and hMEL3) expressing scrambled control shRNA (black) versus two shRNAs against *MCOLN1* (red and blue). The data represent mean ± SD from two independent experiments with 3 replicate cultures per melanocyte line per experiment.\
Statistical significance was assessed using Kruskal-Wallis tests followed by Dunn's multiple comparisons tests (B--G), one-way ANOVA or Kruskal-Wallis tests followed by Dunnett's or Dunn's multiple comparisons tests, respectively, for the last time points measured (H--J), or one-way ANOVA followed by Dunnett's multiple comparisons test (L); ns, not significant; \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1055066-f0002){#F1}

![Loss of *MCOLN1/TRPML1* Impaired Melanoma Cell Survival *In Vitro* and *In Vivo*\
(A) Western blot analysis of TRPML1 and β-actin in melanoma cells derived from 7 patients (melanoma patient-derived xenografts \[PDXs\]: M214, M405, M481, M491, UT10, M528, and M597) and normal melanocytes derived from 3 donors (hMEL). The blot reflects one representative experiment of two performed.\
(B--D) Western blot analysis of TRPML1 and b-actin in parental cells (P) from three melanomas (A375 cell line (B), and M214 (C) and M481 (D) patient-derived melanomas) as well as in 3 clones per melanoma in which *MCOLN1* had been deleted using CRISPR. The blot reflects one representative experiment (of two performed) per melanoma.\
(E--G) Growth in culture of parental cells (black) versus *MCOLN1*-deficient clones (red, blue, and green) in A375 (E), M214 (F), and M481 (G).\
(H and I) Frequencies of activated caspase 3/7^+^ cells (H) and Ki-67^+^ cells (I) among cultured parental cells versus *MCOLN1*-deficient clones.\
(J--L) Growth of subcutaneous tumors in mice transplanted with parental cells versus *MCOLN1*-deficient clones in A375 (J), M214 (K), and M481 (L). Data show mean ± SD from one representative experiment (of two performed) with 5 mice per clone.\
(M and N) Frequencies of activated caspase 3/7^+^ cells (M) and Ki-67^+^ cells (N) in subcutaneous tumors grown from parental cells versus *MCOLN1*-deficient clones. Data represent mean ± SD from two independent experiments with 5 mice per clone per melanoma per experiment.\
Statistical significance was assessed using one-way ANOVA or Welch's one-way ANOVA followed by Dunnett's or Dunnett's T3 multiple comparisons tests, respectively, for the last time point measured (E--G and J--L), or one-way ANOVAs followed by Dunnett's multiple comparisons tests (H and I, M and N). Mean ± SD from two independent experiments with 3 replicate cultures per clone per experiment (E)--(I). ns, not significant; \*\*p \< 0.01; \*\*\*p \< 0.001.\
See also [Figures S2](#SD1){ref-type="supplementary-material"} and [S3](#SD1){ref-type="supplementary-material"}.](nihms-1055066-f0003){#F2}

![*MCOLN1/TRPML1* Deficiency Activated MAPK and mTORC1 Signaling, and MEK Inhibition Blocked the Increase in ERK and mTORC1 Signaling in *MCOLN1*-Deficient Melanoma Cells\
(A--C) Western blots of p-ERK1/2 (T202/Y204), ERK1/2, p-Akt (S473), Akt, p-S6K (T389), S6K, and b-actin in cultured parental cells (P) or *MCOLN1*-deficient cells from A375 (A), M214 (B), or M481 (C) melanomas.\
(D--F) Western blots of p-ERK1/2, ERK1/2, p-TSC2 (S664), TSC2, p-S6K, S6K, and β-actin in cultured parental cells or *MCOLN1*-deficient clones from A375 (D), M214 (E), and M481 (F) treated with DMSO (−) or 5 nM trametinib (MEKi; +).\
(G--I) Western blots of p-MET (Y1234/1235), MET, p-ERBB3 (Y1289), ERBB3, p-ERK1/2, ERK1/2, p-S6K, S6K, and b-actin in cultured parental cells or *MCOLN1*-deficient cells from A375 (G), M214 (H), and M481 (I).\
All blots reflect one representative experiment (of two performed) per melanoma.\
See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1055066-f0004){#F3}

![MET Accumulates in Endosomes in *MCOLN1*-Deficient Cells\
(A--C) Colocalization of MET with the endosomal marker, Rab7, in parental versus *MCOLN1*-deficient cells from A375 (A), M214 (B), and M481 (C) melanomas.\
(D) Manders colocalization coefficients reporting the fraction of MET staining that co-localized with Rab7 staining.\
(E--G) Colocalization of MET with the lysosomal marker, LAMP1, in parental versus *MCOLN1*-deficient cells from A375 (E), M214 (F), and M481 (G) melanomas.\
(H) Manders colocalization coefficients reporting the fraction of MET staining that co-localized with LAMP1 staining.\
All data represent mean ± SD from two independent experiments with 3 quantified cells per clone per experiment. Statistical significance was assessed using unpaired two-tailed t tests; ns, not significant; \*p \< 0.05; \*\*\*p \< 0.001. Scale bars represent 10μm.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1055066-f0005){#F4}

![mTORC1 Inhibition Rescued the Growth of *MCOLN1*-Deficient Cells\
(A--C) Western blots of p-Akt (S473), Akt, p-S6K (T389), S6K, and β-actin in cultured parental cells or *MCOLN1*-deficient clones from A375 (A), M214 (B), and M481 (C) treated with DMSO (−) or 5 nM Torin1 (+). The blot reflects one representative experiment (of three performed) per melanoma.\
(D--F) Growth in culture of parental cells (P; black) versus *MCOLN1*-deficient clones (red, blue, and green) from A375 (D), M214 (E), and M481 (F) treated with DMSO control (solid bars) or 5 nM Torin1 (striped bars) for 21 days. Torin1 treatment significantly rescued the growth of *MCOLN1*-deficient clones. The data represent mean ± SD from two experiments with 3 replicate cultures per clone per experiment.\
(G--I) Growth of subcutaneous tumors in mice transplanted with parental or *MCOLN1*-deficient cells from A375 (G), M214 (H), and M481 (I) and treated with DMSO control (Ctrl; solid lines) or 5 mg/kg/day Rapamycin (Rapa; dotted lines). The data represent mean ± SD from one representative experiment (of two performed) with 5 mice per clone.\
(J--L) Frequency of activated caspase 3/7^+^ cells in subcutaneous tumors grown from parental cells or *MCOLN1*-deficient clones from A375 (J), M214 (K), and M481 (L) treated with DMSO control (solid bars) or rapamycin (striped bars). These data represent mean ± SD from two independent experiments with 4 to 5 mice per clone per experiment.\
Statistical significance was assessed using two-way ANOVAs followed by Sidak's and Dunnett's multiple comparisons tests (D--F), two-way ANOVAs followed by Dunnett's multiple comparisons tests for the last time points measured (G--I), or Welch's one-way ANOVAs or one-way ANOVAs followed by Tamhane's T2, Dunnett's T3, or Dunnett's or Sidak's multiple comparisons tests (J--L); ns, not significant; \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.](nihms-1055066-f0006){#F5}

![*MCOLN1/TRPML1* Deficiency Increased Protein Synthesis and Proteotoxic Stress as a Result of mTORC1 Activation\
(A--C) Relative rate of incorporation of a pulse of OP-Puro in cultured parental cells (P; black) versus *MCOLN1*-deficient clones (red, blue, and green) from A375 (A), M214 (B), and M481 (C) treated with DMSO control (solid bars) or 5 nM Torin1 (striped bars). Data represent mean ± SD from two independent experiments with 3 replicate cultures per treatment per clone per experiment.\
(D--I) Intracellular protein aggregates were visualized by staining with Proteostat dye (D--F) and then quantified (G--I) in parental cells (black) versus *MCOLN1*-deficient clones (red) treated with DMSO control (solid bars) or 5 nM Torin1 (striped bars). Data represent mean ± SD from two independent experiments with 3 replicate cultures per treatment per clone per experiment.\
(J--L) Western blot analysis of BiP, p-eIF2*α* (S51), total eIF2*α*, ATF4, CHOP, p-IRE1*α* (S724), total IRE1*α*, and β-actin in cultured parental cells or *MCOLN1*-deficient cells from A375 (J), M214 (K), and M481 (L) treated with DMSO (−) or 5 nM Torin1 (+). The blot reflects one representative experiment (of two performed) per melanoma. Statistical significance was assessed using two-way ANOVAs followed by Sidak's and Dunnett's multiple comparisons tests (A--C) or two-way ANOVAs followed by Sidak's multiple comparisons tests (G--I); ns, not significant; \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001. Scale bars represent 10μm.\
See also [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms-1055066-f0007){#F6}

![*MCOLN1/TRPML1* Deficiency Impairs Macropinocytosis and Depletes Serine\
(A--D) Macropinocytosis of extracellular protein was measured in cultured parental cells (black) or *MCOLN1*-deficient clones (red) treated with either DMSO control (solid bars) versus 5 nM trametinib (MEKi; striped bars) (A and C) or DMSO control (solid bars) versus 5 nM Torin1 (striped bars) (B and D) by incubating cells with DQ-BSA for 6 h, followed by confocal imaging. The data represent mean ± SD from two independent experiments with 3 replicate cultures per treatment per clone per experiment.\
(E and F) Relative intracellular serine levels in cultured cells (E) or subcutaneous tumors (F) formed by parental cells versus *MCOLN1*-deficient cells treated with DMSO control (solid bars), Torin1 (E; striped bars), or rapamycin (F; striped bars). The data reflect two independent experiments with 3 replicate cultures per clone per treatment per experiment (E) or 5 mice per clone per treatment per experiment (F).\
(G--I) Growth of parental versus *MCOLN1*-deficient cells from A375 (G), M214 (H), and M481 (I) in cultures containing 0.4 mM L-serine (solid bars) or 2 mM L-serine (striped bars) for 21 days. These data represent mean ± SD from two independent experiments with 3 replicate cultures per treatment per clone per experiment.\
(J) Model of TRPML1 function in melanoma cells.\
Statistical significance was assessed using one-way ANOVA or Welch's one-way ANOVA followed by Sidak's or Tamhane's T2 multiple comparisons tests (C and F) or two-way ANOVAs followed by Sidak's and/or Dunnett's multiple comparisons tests (D, E, and G--I); ns, not significant; \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001. Scale bars represent 10μm.\
See also [Figure S7](#SD1){ref-type="supplementary-material"}.](nihms-1055066-f0008){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                     SOURCE                            IDENTIFIER
  ------------------------------------------------------- --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibodies                                                                                
  Anti-Mouse CD31 (PECAM-1) eFluor 450                    eBiosciences                      Cat\# 48-0311-82, RRID:AB_10598807
  Anti-Mouse TER-119 violetFluor450                       Tonbo                             Cat\# 75-5921, RRID:AB_2621967
  Anti-Mouse CD45, violetFluor450                         Tonbo                             Cat\# 75-0451, RRID:AB_2621947
  Anti-human HLA-ABC, APC                                 BD Pharmigen                      Cat\# 555555, RRID:AB_398603
  Goat anti-mouse IgG, Alexa Fluor 488-conjugated         ThermoFisher Scientific           Cat\# A-11029, RRID:AB_138404
  Donkey anti-rabbit IgG, Alexa Fluor 488-conjugated      Jackson ImmunoResearch            Cat\# 711-546-152, RRID:AB_2340619
  Donkey anti-mouse IgG, Alexa Fluor 647-conjugated       Jackson ImmunoResearch            Cat\# 715-605-150, RRID:AB_2340862
  Anti-Ki-67                                              Agilent                           Cat\# M7240, RRID:AB_2142367
  Anti-Rab7                                               Cell Signaling                    Cat\# 95746, RRID:AB_2800252
  Anti-LAMP-1                                             Santa Cruz                        Cat\# sc-20011, RRID:AB_626853
  Anti-rabbit IgG, HRP-linked                             Cell Signaling                    Cat\# 7074, RRID:AB_2099233
  Anti-mouse IgG, HRP-linked                              Cell Signaling                    Cat\# 7076, RRID:AB_330924
  Anti-MCOLN1                                             Sigma                             Cat\# AV35307, RRID:AB_1853643
  Anti-phospho-ERK1/2                                     Cell Signaling                    Cat\# 4370, RRID:AB_2315112
  Anti-ERK1/2                                             Cell Signaling                    Cat\# 4695, RRID:AB_390779
  Anti-phospho-Akt                                        Cell Signaling                    Cat\# 4060, RRID:AB_2315049
  Anti-Akt                                                Cell Signaling                    Cat\# 4691, RRID:AB_915783
  Anti-phospho-p70 S6 kinase                              Cell Signaling                    Cat\# 9234, RRID:AB_2269803
  Anti-p70 S6 kinase                                      Cell Signaling                    Cat\# 2708, RRID:AB_390722
  Anti-phospho-MET                                        Cell Signaling                    Cat\# 3077, RRID:AB_2143884
  Anti-MET                                                Cell Signaling                    Cat\# 8198, RRID:AB_10858224
  Anti-phospho-ERBB3                                      Cell Signaling                    Cat\# 2842, RRID:AB_11178795
  Anti-ERBB3                                              Cell Signaling                    Cat\# 12708, RRID:AB_2721919
  Anti-BiP                                                Cell Signaling                    Cat\# 3177, RRID:AB_2119845
  Anti-phospho-eIF2α                                      Cell Signaling                    Cat\# 3398, RRID:AB_2096481
  Anti-eIF2α                                              Cell Signaling                    Cat\# 5324, RRID:AB_10692650
  Anti-ATF4                                               Cell Signaling                    Cat\# 11815, RRID:AB_2616025
  Anti-CHOP                                               Cell Signaling                    Cat\# 5554, RRID:AB_10694399
  Anti-phospho-IRE1α                                      Invitrogen                        Cat\# PA1-16927, RRID:AB_2262241
  Anti-IRE1α                                              Cell Signaling                    Cat\# 3294, RRID:AB_823545
  Anti-β-actin                                            Cell Signaling                    Cat\# 8457, RRID:AB_10950489
  Bacterial and Virus Strains                                                               
  DH5α Competent *E. coli*                                Generated in-lab                  N/A
  Stbl3 Competent *E. coli*                               Generated in-lab                  N/A
  Biological Samples                                                                        
  Patient-derived melanoma xenografts (PDX)               [@R22]; [@R52]; [@R54]            N/A
  Adult human melanocytes                                 ATCC                              Cat\# PCS-200-013
  Adult human melanooytes                                 Invitrogen                        Cat\# C-024-5C
  Adult human melanocytes                                 Lonza                             Cat\# CC-2586
  Chemicals, Peptides, and Recombinant Proteins                                             
  Trametinib (GSK1120212)                                 Selleckchem                       Cat\# S2673, CAS:871700-17-3
  Torin1                                                  Tocris                            Cat\# 4247, CAS:1222998-36-8
  Rapamycin (Sirolimus)                                   LC Laboratories                   Cat\# R-5000, CAS:53123-88-9
  Bafilomycin A1                                          Sigma Aldrich                     Cat\# B1793, CAS:88899-55-2
  O-propargyl-puromycin (OP Puromycin)                    Medchem Source                    Cat\# JA-1024, CAS: 1416561-90-4
  Puromycin dihydroohloride                               Sigma Aldrich                     Cat\# P8833, CAS:58-58-2
  PD169316                                                Sigma Aldrich                     Cat\# P9248, CAS:152121-53-4
  DQ-BSA Green                                            Fisher Scientific                 Cat\# D12050
  L-serine                                                Sigma Aldrich                     Cat\# S4500, CAS:56-45-1
  DMEM, high glucose                                      Fisher Scientific                 Cat\# 11965118
  Foundation B fetal bovine serum (FBS)                   Gemini                            Cat\# 900-208
  Penicillin/Streptomycin solution                        Fisher                            Cat\# 15140-122
  Collagenase Type IV                                     Worthington                       Cat\# LS004189
  DNase I from bovine pancreas                            Sigma Aldrich                     Cat\# D4527, CAS:9003-98-9
  Calcium chloride                                        Sigma Aldrich                     Cat\# C5670, CAS: 10043-52-4
  Superscript III Reverse Transcriptase                   Thermo Fisher                     Cat\# 18080044
  Polyjet                                                 SignaGen                          Cat\# SL100688
  Prime-XV Tumorsphere SFM                                Irvine Scientific                 Cat\# 91130
  Heparin sodium salt                                     Sigma Aldrich                     Cat\# H3149, CAS:9041-08-1
  Hydrocortisone                                          Sigma Aldrich                     Cat\# H0135, CAS:50-23-7
  B-27                                                    Thermo Fisher                     Cat\# 17504044
  StemRegenin 1                                           StemCell Technologies, Inc.       Cat\# 72344, CAS:1227633-49-9
  Charcoal stripped FBS                                   Thermo Fisher                     Cat\# 12676011
  Bovine Pituitary Extract (BPE)                          Lonza                             Cat\# CC-4009
  Recombinant human IL-8 (CXCL8)                          Peprotech                         Cat\# 200-08M
  Recombinant human GRO-α/MGSA (CXCL1)                    Peprotech                         Cat\# 300-11
  Recombinant human HGF                                   Peprotech                         Cat\# 100-39H
  QuickExtract                                            Epicenter                         Cat\# QE09050
  Leibovitz L-15                                          Life Technologies                 Cat\# 21083-027
  1M HEPES                                                Life Technologies                 Cat\# 15630-080
  Bovine Serum Albumin                                    Sigma Aldrich                     Cat\# A7906, CAS:9048-46-8
  Corning Matrigel Matrix - High                          Fisher Scientific                 Cat\# 354248
  (Hydroxypropyl)methyl cellulose                         Sigma Aldrich                     Cat\# H7509, CAS:9004-65-3
  Tween 80                                                Sigma Aldrich                     Cat\# P1754, CAS:9005-65-6
  Dimethyl sulfoxide (DMSO)                               Sigma Aldrich                     Cat\# D4540, CAS:67-68-5
  HBSS w/o phenol red, Ca and Mg                          Fisher Scientific                 Cat\# MT21022CV
  Phosphate Buffered Saline (PBS), 1X                     VWR                               Cat\# 45000-446
  4',6-diamidino-2-phenylindole (DAPI)                    Sigma Aldrich                     Cat\# D8417, CAS:28718-90-3
  0.25% Trypsin                                           Fisher Scientific                 Cat\# SH3004201
  4% Parafomaldehyde in PBS                               Fisher Scientific                 Cat\# AAJ19943K2, CAS:30525-89-4
  Sucrose                                                 Sigma Aldrich                     Cat\# S0389, CAS:57-50-1
  FB OCT Compound CLR                                     Fisher Scientific                 Cat\# 23-730-571
  Triton X-100                                            Sigma Aldrich                     Cat\# T8787, CAS:9002-93-1
  Normal Goat serum                                       Jackson ImmunoResearch            Cat\# 005-000-121
  Normal Donkey serum                                     Jackson ImmunoResearch            Cat\# 017-000-121
  Fluoromount-G                                           Fisher Scientific                 Cat\# OB100-01
  In-Fusion HD Cloning Plus                               Clontech                          Cat\# 638909
  Hexadimethrine bromide (polybrene)                      Sigma Aldrich                     Cat\# 107689, CAS:28728-55-4
  ZR-96 Quick-gDNA                                        Zymo Research                     Cat\# D3011
  QIAquick Gel Extraction Kit                             QIAGEN                            Cat\# 28704
  QIAprep Spin Miniprep Kit                               QIAGEN                            Cat\# 27106
  RIPA Buffer (10X)                                       Cell Signaling                    Cat\# 9806S
  Tris Base                                               Fisher Scientific                 Cat\# BP152, CAS:77-86-1
  Hydrochloric Acid                                       Fisher Scientific                 Cat\# A144SI-212, CAS:7646-01-0
  Sodium Chloride                                         Research Products International   Cat\# S23020, CAS:7647-14-5
  EDTA, pH 8.0                                            Thermo Fisher                     Cat\# AM9260G, CAS:6381-92-6
  10X Tris/Glycine/SDS Buffer                             BioRad                            Cat\# 161-0732
  Tween 20                                                Sigma                             Cat\# P1379, CAS:9005-64-5
  Clarity Western ECL Substrate                           BioRad                            Cat\# 170-5061
  SuperSignal West Femto Maximum                          Thermo Scientific                 Cat\# 34095
  Restore Western Blot Stripping Buffer                   Thermo Fisher                     Cat\# 21059
  Saponin                                                 Sigma Aldrich                     Cat\# 47036, CAS:8047-15-2
  Alexa Fluor 555 Azide                                   Thermo Fisher                     Cat\# A20012
  Hoechst 33342                                           Thermo Fisher                     Cat\# 62249, CAS:23491-52-3
  Methanol, Optima LC/MS Grade                            Fisher Scientific                 Cat\# A456, CAS:67-56-1
  Ammonium Acetate, Optima LC/MS Grade                    Fisher Scientific                 Cat\# A11450, CAS:631 −61 −8
  Acetonitrile, Optima LC/MS Grade                        Fisher Scientific                 Cat\# A955, CAS:75-05-8
  Critical Commercial Assays                                                                
  CellEvent Caspase-3/7 Green                             Thermo Fisher                     Cat\# C10423
  Click-iT Cell Reaction Buffer Kit                       Thermo Fisher                     Cat\# C10276
  Proteostat Aggresome Detection Kit                      Enzo                              Cat\# ENZ-51023
  Pierce BCA Protein Assay Kit                            Thermo Fisher                     Cat\# 23227
  MycoAlert Detection Kit                                 Lonza                             Cat\# LT07-218
  Deposited Data                                                                            
  Analyzed shRNA screen data                              This paper                        <https://doi.org/10.17632/ndxtvbg4ty.1>
  Experimental Models: Cell Lines                                                           
  A375 melanoma cell line                                 ATCC                              Cat\# CRL-1619, RRID:CVCL_0132
  HEK293T cell line                                       ATCC                              Cat\# CRL-3216, RRID:CVCL_0063
  Experimental Models: Organisms/Strains                                                    
  NOD.CB17-Prkdc^scid^ Il2rg^tm1Wjl^/SzJ (NSG) mice       The Jackson Laboratory            Cat\# 005557
  Oligonucleotides                                                                          
  MCOLN1_E2_sgRNA_1\_F: AAACTCGCCGTCGTC TCAAATACTC        This paper                        N/A
  MCOLN1_E2_sgRNAJ_R:CACCGAGTATTTGAG ACGACGGCGA           This paper                        N/A
  MCOLN1_E2_sgRNA_2\_F: AAACTGCGACAAGTTT CGAGCCAAC        This paper                        N/A
  MCOLN1_E2_sgRNA_2\_R: CACCGTTGGCTCGAA ACTTGTCGCA        This paper                        N/A
  MCOLN1_qPCR_F:CTGATGCTGCAAGTGGTCAAG                     This paper                        N/A
  MCOLN1_qPCR_R:GGTGTTCTCTTCCCGGAATGTC                    This paper                        N/A
  MCOLN1 \_pLOC_F: ggtaccgagctcggatccATGACAGC CCCGGCGGG   This paper                        N/A
  MCOLN1 \_pLOC_R: cccggttcattagctagcTCAATTCA CCAGCAGCG   This paper                        N/A
  Recombinant DNA                                                                           
  pLOC-MCOLN1                                             Generated in-lab                  N/A
  pLOC-RFP                                                Dharmacon                         Cat\# OHS5832
  pSpCas9(BB)-2A-GFP (PX458)                              Addgene                           Cat\# 48318, RRID:Addgene_48138
  pANT7_cGST_MCOLN1                                       DNASU                             Clone\# HsCD00732386
  psPAX2                                                  Addgene                           Cat\# 12260, RRID:Addgene_12260
  pMD2.G                                                  Addgene                           Cat\# 12259, RRID:Addgene_12259
  Software and Algorithms                                                                   
  BD FACSDiva 8.0                                         BD Biosciences                    <http://www.bdbiosciences.com/in/instruments/software/facsdiva/>
  FlowJo V10                                              BD Biosciences                    <https://www.flowjo.com/>
  Zeiss ZEN 2.3                                           Zeiss                             <https://www.zeiss.com/microscopy/us/products/microscope-software/zen.html>
  AutoQuant X3                                            Media Cybernetics                 <http://www.mediacy.com/autoquantx3>
  lmaris V7.7.2                                           Bitplane                          <http://www.bitplane.com/imaris77.aspx>
  Analyst v1.6.3                                          SCIEX                             <https://sciex.com/products/software/analyst-software>
  XCalibur 4.1.50                                         Thermo Scientific                 <https://www.thermofisher.com/order/catalog/product/OPTON-30487>
  Multiquant v2.1.1                                       SCIEX                             <https://sciex.com/products/software/multiquant-software>
  Compound Discoverer 3.0                                 Thermo Scientific                 <https://www.thermofisher.com/us/en/home/industrial/mass-spectrometry/liquid-chromatography-mass-spectrometry-Ic-ms/lc-ms-software/multi-omics-data-analysis/compound-discoverer-software.html>
  Trace Finder 4.1                                        Thermo Scientific                 <https://www.thermofisher.com/order/catalog/product/OPTON-30626>
  Prism 8                                                 Graphpad                          <https://www.graphpad.com/scientific-software/prism/>
  R 3.5.1                                                 R-Project                         <https://www.r-project.org/>
  Stats package                                           RDocumentation                    <https://www.rdocumentation.org/packages/stats/versions/3.5.3>
  fBasics package                                         R-Project                         <https://cran.r-project.org/web/packages/fBasics/index.html>
  Car package                                             R-Project                         <https://cran.r-project.org/web/packages/car/index.html>
  Cutadapt                                                [@R42]                            <https://cutadapt.readthedocs.io/en/stable/>
  Bowtie 2                                                [@R34]                            <http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>
  Other                                                                                     
  shRNA-Non-targeting                                     Dharmacon                         Cat\# RHS4349
  shRNA-Non-targeting                                     Dharmacon                         Cat\# RHS4346
  Ion Channel GIPZ shRNA library                          Dharmacon                         Cat\# RHS6045
  Custom GIPZ shRNA library                               Dharmacon                         Ref\# SO-2439595G
  shRNA-EIF3A                                             Dharmacon                         Cat\# RHS4430-200163810
  shRNA-EIF3A                                             Dharmacon                         Cat\# RHS4430-200198846
  shRNA-EIF3A                                             Dharmacon                         Cat\# RHS4430-99293356
  4--20% polyacrylamide tris glycine SDS gel              BioRad                            Cat\# 4561095
  Trans-Blot Turbo Mini Transfer kit, PVDF                BioRad                            Cat\# 1704272

###### Highlights

-   TRPML1 is preferentially required for the survival and proliferation of melanoma cells

-   TRPML1 negatively regulates MAPK and mTORC1 signaling in melanoma cells

-   Macropinocytosis is upregulated in melanoma cells as compared to normal melanocytes

-   TRPML1 promotes protein homeostasis and sustains macropinocytosis in melanoma cells
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